Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world.
At Novartis, we invest in the most promising frontiers of science, the most exciting innovations in the business of medicine, and the most significant healthcare needs. In this exhibition designed by Nuevo Design FZ LLC, the Swiss company will display its four pillars.
The four pillars of Novartis
At Novartis, we invest in the most promising frontiers of science, the most exciting innovations in the business of medicine, and the most significant healthcare needs. During Novartis Presence at the Dubai EXPO 2020, we are presenting our four pillars:
- Data Science & Artificial Intelligence
Novartis has embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies. We are integrating data science and digital technologies into drug discovery (research & development) and health delivery. Artificial Intelligence (AI) at Novartis is a place to innovate, experiment and scale AI-based solutions. We are aiming, together with our partners, to transform how we create innovative medicines, engage with patients and health care providers and improve operational efficiency.
- Cell & Gene Therapy
Novartis is advancing research and development of new therapies in many disease areas and building new technology platforms; like: cell and gene therapies & radioligand therapies. Novartis is dedicated to developing and commercializing gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. Each cell and gene therapy is designed based on detailed information about the roots of a patient’s disease. It treats a condition at its source, repairing or enhancing cells at the genetic level. At Novartis, we’re collaborating on the cell and gene therapy frontier to bring this revolutionary approach to patients with a variety of diseases, including genetic disorders and certain deadly cancers. Cell and gene therapies are designed to halt a disease in its tracks or reverse its progress rather than simply manage symptoms. These are often one-time treatments that may alleviate the underlying cause of a disease, and they have the potential to cure certain conditions. In contrast, many conventional medicines must be taken on a continual basis for weeks or months, or even for life.
- Building trust with Society
As a global company, Novartis has a great responsibility and an even greater opportunity to lead the world in creating a positive social change. We can help catalyze a global response to complex challenges, such as the COVID-19 pandemic and climate change, by embracing societal impact as a core business objective. Building trust with society is a key pillar of the Novartis corporate strategy and defines our focus areas for managing environmental, social and corporate governance topics: being part of the solution on pricing and access, tackling global health challenges, being a responsible citizen, and holding ourselves to high ethical standards. We are following an integrated approach across these global efforts, and are on a journey to create a culture in which ESG activities are deeply embedded in our daily work.
- Patient Community
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Our significant investment in research and development underpins our commitment to using science-based innovation to address some of society’s most challenging healthcare issues. Only by working together can we improve outcomes for patients and change the practice of medicine. We recognize the importance of patients and caregivers understanding what they can expect from Novartis and we commit to actively seeking out and listening to insights from the patient community for the mutual benefit of patients, healthcare systems and Novartis.